A PHASE 1, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF VONOPRAZAN- OR ESOMEPRAZOLE-BASED BISMUTH-CONTAINING QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION IN CHINA

Jia Miao  1     Chao Hu  1     Jie Tang  1     Wenyan Wang  2     Ying Wang  2     Ruoting Men  2     Li Yang  2     Liqun Gu  3     Naoki Yoshida  4     Richard Czerniak  5    
1 West China Hospital, Sichuan University, Chengdu, China
2 ICU, West China Hospital, Sichuan University, Chengdu, China
3 Takeda Development Center Asia, Shanghai, China
4 Takeda Development Center Japan, Osaka, Japan
5 Takeda Pharmaceuticals International Co, Massachusetts, United States

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing